Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Merck,
known as MSD outside the United States and Canada, has received approval
for NOXAFIL® (posaconazole) 300 mg Concentrate for Solution for Infusion
from the European Medicines Agency (EMA). Ligand earns a $550,000
milestone payment as a result of the approval.
for Ligand Earns Milestone Payment Triggered by EU Approval of Merck’s Captisol-enabled NOXAFIL® (posaconazole) Concentrate for Solution for Infusion investment picks